JP2016537347A - アザインドール化合物の製剤 - Google Patents

アザインドール化合物の製剤 Download PDF

Info

Publication number
JP2016537347A
JP2016537347A JP2016529960A JP2016529960A JP2016537347A JP 2016537347 A JP2016537347 A JP 2016537347A JP 2016529960 A JP2016529960 A JP 2016529960A JP 2016529960 A JP2016529960 A JP 2016529960A JP 2016537347 A JP2016537347 A JP 2016537347A
Authority
JP
Japan
Prior art keywords
compound
pharmaceutical composition
weight
hcl salt
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016529960A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016537347A5 (enExample
Inventor
エリック アーサー シモーネ，
エリック アーサー シモーネ，
タパン サンビ，
タパン サンビ，
アラメル バンダ，
アラメル バンダ，
キャサリン スタブロポロス，
キャサリン スタブロポロス，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vertex Pharmaceuticals Inc
Original Assignee
Vertex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52001095&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2016537347(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vertex Pharmaceuticals Inc filed Critical Vertex Pharmaceuticals Inc
Publication of JP2016537347A publication Critical patent/JP2016537347A/ja
Publication of JP2016537347A5 publication Critical patent/JP2016537347A5/ja
Priority to JP2021152005A priority Critical patent/JP2021191796A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2016529960A 2013-11-13 2014-11-12 アザインドール化合物の製剤 Pending JP2016537347A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021152005A JP2021191796A (ja) 2013-11-13 2021-09-17 アザインドール化合物の製剤

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361903840P 2013-11-13 2013-11-13
US61/903,840 2013-11-13
PCT/US2014/065144 WO2015073491A1 (en) 2013-11-13 2014-11-12 Formulations of azaindole compounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021152005A Division JP2021191796A (ja) 2013-11-13 2021-09-17 アザインドール化合物の製剤

Publications (2)

Publication Number Publication Date
JP2016537347A true JP2016537347A (ja) 2016-12-01
JP2016537347A5 JP2016537347A5 (enExample) 2017-12-21

Family

ID=52001095

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016529960A Pending JP2016537347A (ja) 2013-11-13 2014-11-12 アザインドール化合物の製剤
JP2021152005A Pending JP2021191796A (ja) 2013-11-13 2021-09-17 アザインドール化合物の製剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021152005A Pending JP2021191796A (ja) 2013-11-13 2021-09-17 アザインドール化合物の製剤

Country Status (13)

Country Link
US (3) US20160250213A1 (enExample)
EP (1) EP3068434A1 (enExample)
JP (2) JP2016537347A (enExample)
KR (1) KR20160084465A (enExample)
CN (1) CN105848683A (enExample)
AU (1) AU2014348762A1 (enExample)
CA (1) CA2930105A1 (enExample)
CL (1) CL2016001111A1 (enExample)
IL (2) IL245587A0 (enExample)
MX (1) MX2016006197A (enExample)
RU (1) RU2685730C1 (enExample)
SG (1) SG10201804024VA (enExample)
WO (1) WO2015073491A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190092545A (ko) * 2016-12-15 2019-08-07 선샤인 레이크 파르마 컴퍼니 리미티드 인플루엔자 바이러스 복제의 억제제 및 이의 용도
JP2020516634A (ja) * 2017-04-12 2020-06-11 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ インフルエンザウイルス感染の処置方法および併用療法

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY32717A (es) 2009-06-17 2011-01-31 Vertex Pharma Inhibidores de la replicación de virus de la gripe
UA118010C2 (uk) 2011-08-01 2018-11-12 Вертекс Фармасьютікалз Інкорпорейтед Інгібітори реплікації вірусів грипу
SI3068776T1 (sl) 2013-11-13 2019-09-30 Vertex Pharmaceuticals Incorporated Inhibitorji replikacije virusov influence
RU2019104421A (ru) 2013-11-13 2019-04-17 Вертекс Фармасьютикалз Инкорпорейтед Способы получения ингибиторов репликации вирусов гриппа
EP3294717B1 (en) 2015-05-13 2020-07-29 Vertex Pharmaceuticals Inc. Methods of preparing inhibitors of influenza viruses replication
EP3294735B8 (en) 2015-05-13 2022-01-05 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
JP6952695B2 (ja) 2015-12-09 2021-10-20 サンシャイン・レイク・ファーマ・カンパニー・リミテッドＳｕｎｓｈｉｎｅ Ｌａｋｅ Ｐｈａｒｍａ Ｃｏ．，Ｌｔｄ． インフルエンザウイルス複製の阻害剤、その適用方法および使用
CN107759571B (zh) 2016-08-16 2021-03-02 广东东阳光药业有限公司 流感病毒复制抑制剂及其使用方法和用途
US10647693B2 (en) 2016-08-30 2020-05-12 North & South Brother Pharmacy Investment Company Limited Inhibitors of influenza virus replication, application methods and uses thereof
US11098042B2 (en) 2017-01-05 2021-08-24 Sunshine Lake Pharma Co., Ltd. Inhibitors of influenza virus replication and uses thereof
WO2018137670A1 (zh) * 2017-01-24 2018-08-02 苏州科睿思制药有限公司 一种病毒蛋白抑制剂药物vx-787的晶型及其制备方法和用途
CN110446711B (zh) 2017-03-02 2022-02-15 广东东阳光药业有限公司 流感病毒复制抑制剂及其用途
ES2959886T3 (es) * 2017-08-31 2024-02-28 Novartis Ag Método para preparar gránulos
EP3774794A1 (en) * 2018-04-06 2021-02-17 Janssen Pharmaceuticals, Inc. Isothermal reactive crystallisation process for the preparation of a crystalline form of pimodivir hydrochloride hemihydrate
WO2020058745A1 (en) * 2018-09-18 2020-03-26 Shionogi & Co., Ltd. Treating influenza using substituted polycyclic pyridone derivatives and prodrugs thereof
AU2019380421B2 (en) * 2018-11-13 2025-07-24 Cocrystal Pharma, Inc. Formulations of influenza therapeutics
KR20200106607A (ko) * 2019-03-05 2020-09-15 주식회사 코아팜바이오 오셀타미비르 함유 의약 조성물
TW202114678A (zh) * 2019-06-20 2021-04-16 美商健生醫藥公司 氮雜吲哚化合物之調配物
CN112578034B (zh) * 2020-11-04 2022-02-11 广东众生睿创生物科技有限公司 一种手性胺小分子及其盐的质量控制方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012530713A (ja) * 2009-06-17 2012-12-06 バーテックス ファーマシューティカルズ インコーポレイテッド インフルエンザウイルス複製の阻害剤

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5681815A (en) * 1993-06-28 1997-10-28 Sophie Chen Antiviral and antitumor agents
EP1827499A4 (en) * 2004-11-24 2010-03-17 Medpointe Healthcare Inc COMPOSITIONS COMPRISING AZELASTIN AND METHODS OF USE
WO2010143207A1 (en) * 2009-06-11 2010-12-16 Rubicon Research Private Limited Taste-masked oral formulations of influenza antivirals

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012530713A (ja) * 2009-06-17 2012-12-06 バーテックス ファーマシューティカルズ インコーポレイテッド インフルエンザウイルス複製の阻害剤

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
シクロデキストリンの応用技術≪普及版≫, vol. 普及版、第１刷, JPN6019048192, July 2013 (2013-07-01), pages 40 - 41, ISSN: 0004169913 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190092545A (ko) * 2016-12-15 2019-08-07 선샤인 레이크 파르마 컴퍼니 리미티드 인플루엔자 바이러스 복제의 억제제 및 이의 용도
JP2020513415A (ja) * 2016-12-15 2020-05-14 ノース・アンド・サウス・ブラザー・ファーマシー・インベストメント・カンパニー・リミテッド インフルエンザウイルス複製の阻害剤及びその使用
JP7034162B2 (ja) 2016-12-15 2022-03-11 サンシャイン・レイク・ファーマ・カンパニー・リミテッド インフルエンザウイルス複製の阻害剤及びその使用
KR102554019B1 (ko) 2016-12-15 2023-07-11 선샤인 레이크 파르마 컴퍼니 리미티드 인플루엔자 바이러스 복제의 억제제 및 이의 용도
JP2020516634A (ja) * 2017-04-12 2020-06-11 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ インフルエンザウイルス感染の処置方法および併用療法

Also Published As

Publication number Publication date
CN105848683A (zh) 2016-08-10
RU2016122609A (ru) 2017-12-18
US20160250213A1 (en) 2016-09-01
IL245587A0 (en) 2016-06-30
WO2015073491A1 (en) 2015-05-21
RU2685730C1 (ru) 2019-04-23
MX2016006197A (es) 2016-08-08
IL278214A (en) 2020-11-30
CA2930105A1 (en) 2015-05-21
AU2014348762A1 (en) 2016-05-26
EP3068434A1 (en) 2016-09-21
US20180318301A1 (en) 2018-11-08
CL2016001111A1 (es) 2017-06-09
US20210008072A1 (en) 2021-01-14
KR20160084465A (ko) 2016-07-13
JP2021191796A (ja) 2021-12-16
SG10201804024VA (en) 2018-07-30

Similar Documents

Publication Publication Date Title
US20210008072A1 (en) Formulations of azaindole compounds
JP6615755B2 (ja) インフルエンザウイルスの複製の阻害剤
JP6618901B2 (ja) インフルエンザウイルスの複製の阻害剤を調製する方法
CN110603041A (zh) 用于治疗流感病毒感染的组合治疗
JP2018515527A (ja) インフルエンザウイルスの複製の阻害剤
US20200397784A1 (en) Formulations of azaindole compounds
HK40018796A (en) Inhibitors of influenza viruses replication
HK1227859B (en) Inhibitors of influenza viruses replication
HK1227859A1 (en) Inhibitors of influenza viruses replication

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171109

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20171109

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180711

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180711

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20181010

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20181205

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190111

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190508

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190909

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20190909

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20190919

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20191018

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20191021

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20191206

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20191210

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20200603

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20201209

C13 Notice of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: C13

Effective date: 20210317

C28A Non-patent document cited

Free format text: JAPANESE INTERMEDIATE CODE: C2838

Effective date: 20210317

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20210407

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210610

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20210830

C23 Notice of termination of proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C23

Effective date: 20211020

C03 Trial/appeal decision taken

Free format text: JAPANESE INTERMEDIATE CODE: C03

Effective date: 20211117

C30A Notification sent

Free format text: JAPANESE INTERMEDIATE CODE: C3012

Effective date: 20211117